Candel Therapeutics Inc (CADL)

Name: Candel Therapeutics Inc (CADL) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Candel Therapeutics Inc (CADL)

Stock Card

$13.03

$0.06 (0.46%)

As on 04-Sep-2026 13:39EDT

Market cap

$1,000 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

8.3

Div. Yield

0 %

Candel Therapeutics Inc (CADL) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 12.77 High: 13.05

52 Week Range

Low: 4.35 High: 14.00

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.8 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0
Debt to Equity

0
Book Value

$--
EPS

$-1.4
Face value

--
Shares outstanding

76,518,565

5 Years Aggregate

CFO

$-102.13 Mln

EBITDA

$-140.14 Mln

Net Profit

$-107.12 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Candel Therapeutics Inc (CADL)	130.6	29.4	48.1	155.2	120.8	9.8	--
BSE Sensex	-9.6	-2.7	2.9	-5.0	5.4	5.7	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 04-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022
Candel Therapeutics Inc (CADL)	-34.9	482.0	-17.9	-77.1
S&P Small-Cap 600	4.0	7.0	13.9	-17.4
BSE Sensex	9.1	8.1	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Candel Therapeutics Inc (CADL)	13.0	1,000.1	0.0	-88.5	--	-99.4	--	8.3
Arrowhead Pharmaceuticals (ARWR)	84.8	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Cytokinetics Inc (CYTK)	72.4	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	59.0	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	110.2	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	355.5	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Kymera Therapeutics (KYMR)	118.2	9,718.7	105.0	-299.7	-227.2	-19.4	--	6.6
Madrigal Pharmaceuticals (MDGL)	541.4	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	592.0	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Nuvalent Inc (NUVL)	124.0	9,808.7	0.0	-450.1	--	-44.6	--	8.4

Shareholding Pattern

View Details

About Candel Therapeutics Inc (CADL)

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the... treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts. Read more

President, CEO & Director

Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.
President, CEO & Director

Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
Headquarters

Needham, MA
Website

https://www.candeltx.com

FAQs for Candel Therapeutics Inc (CADL)

What is the current share price of Candel Therapeutics Inc (CADL) Today?

The share price of Candel Therapeutics Inc (CADL) is $13.03 (NASDAQ) as of 04-Sep-2026 13:39 EDT. Candel Therapeutics Inc (CADL) has given a return of 120.83% in the last 3 years.

What is the current PB & PE ratio of Candel Therapeutics Inc (CADL)?

Since, TTM earnings of Candel Therapeutics Inc (CADL) is negative, P/E ratio is not available.
The P/B ratio of Candel Therapeutics Inc (CADL) is 8.34 times as on 28-Aug-2026, a 61 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-8.12	5.97
2024	-5.59	4.65
2023	-1.12	3.34
2022	-2.75	1.08
2021	-5.05	2.84

What is the 52 Week High and Low of Candel Therapeutics Inc (CADL)?

The 52-week high and low of Candel Therapeutics Inc (CADL) are Rs 14.00 and Rs 4.35 as of 05-Sep-2026.

What is the market cap of Candel Therapeutics Inc (CADL)?

Candel Therapeutics Inc (CADL) has a market capitalisation of $ 1,000 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Candel Therapeutics Inc (CADL)?

Before investing in Candel Therapeutics Inc (CADL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.